Stenosis News and Research

RSS

A stenosis is an abnormal narrowing in a blood vessel or other tubular organ or structure.

Interventional Spine to present at and participate as sponsor of Spine Technology Summit

Interventional Spine, Inc., a privately held medical device manufacturer focusing on diseases of the spine, will present at the Spine Technology Summit at the Roosevelt Hotel in New Orleans on Monday April 26th. This annual event is a showcase for 40 new technology companies and attracts investors, industry, practitioners and analysts.

22 Apr 2010

Surgical treatment for certain injuries helps NFL athletes return to the game faster

The Bonati Spine Institute, the leading center for the patented Bonati Spine Procedures for minimally invasive laser spine surgery, reports that recent studies indicate that surgical intervention is the best treatment option for certain back injuries.

21 Apr 2010

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal study, the novel technique achieved better results at a lower dose than conventional non-magnetic stent therapy.

20 Apr 2010

First US implant of Interventional Spine's RENEW Interspinous Allograft Technology for LSS

Interventional Spine, Inc. today announced the first commercial implant in the United States of its RENEW™ Interspinous Allograft Technology for the Treatment of Lumbar Spinal Stenosis (LSS).

19 Apr 2010

Alphatec Holdings prices underwritten public offering of common stock

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that is has priced an underwritten public offering of 16,000,000 shares of common stock, consisting of 8,000,000 shares to be sold by the Company and 8,000,000 shares to be sold by a selling shareholder, HealthpointCapital Partners, L.P., at a price to the public of $5.00 per share.

16 Apr 2010

Alphatec Holdings proposes 8 million common stock public offering

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announced that it is offering to sell 8,000,000 primary shares of its common stock and a selling shareholder, HealthpointCapital Partners, L.P., is offering 8,000,000 shares of Alphatec common stock in an underwritten public offering.

12 Apr 2010

Alphatec Spine's first-quarter preliminary consolidated revenues up 25.6%

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions related to the aging spine, announces today that, based on preliminary financial data, the Company will report record consolidated quarterly revenues of approximately $38.4 million for the first quarter 2010, an increase of 25.6% from the $30.6 million reported for the first quarter 2009.

12 Apr 2010

Complex back surgeries skyrocket, raising concerns about cost, complications

NPR: "Too many complex back surgeries are being done and people are suffering as a result, according to a study in the current issue of the Journal of the American Medical Association. The general tendency noted in the study — that many patients and doctors think more medical care is always better — has implications for the new health overhaul law.

8 Apr 2010

Frequency of complex fusion procedures for lower back increased among Medicare recipients

The frequency of complex fusion procedures to treat spinal stenosis of the lower back increased between 2002-2007 among Medicare recipients, while the rates of decompression and simple fusion procedures decreased, according to a study in the April 7 issue of JAMA.

7 Apr 2010

Medtronic to appeal U.S. jury verdict in CoreValve system patent infringement case

Medtronic, Inc., announced today that it will appeal the $73.5 million jury verdict returned in the U.S. District Court in Delaware deciding that the CoreValve® transcatheter aortic valve system infringes a valid U.S. Andersen patent owned by Edwards Lifesciences.

2 Apr 2010

Enrollment complete in Paradigm Spine's comparative study of coflex interlaminar technology

Paradigm Spine, LLC, a developer of innovative non-fusion and fusion spinal implant solutions, announced today that it has completed patient enrollment in an Investigational Device Exemption pivotal clinical study comparing the coflex® interlaminar technology to instrumented posterolateral fusion in the surgical treatment of spinal stenosis.

30 Mar 2010

Alphatec Holdings closes acquisition of Scient'x Groupe

Alphatec Holdings, Inc., the parent company of Alphatec Spine, Inc., a medical device company that designs, develops, manufactures and markets products for the surgical treatment of spine disorders, with a focus on treating conditions affecting the aging spine, announced today the closing of its previously announced acquisition of Scient'x Groupe SAS, a spinal implant company headquartered in France.

29 Mar 2010

AngioScore receives FDA marketing clearance for PTA Scoring Balloon Catheter

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, announced today that the company has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its AngioSculpt® PTA Scoring Balloon Catheter for dilatation of lesions in renal arteries.

26 Mar 2010

NIH grants $1.4 Million to WPI to continue study of arterial plaque

A Worcester Polytechnic Institute research team has received a four-year, $1.4 million award from the National Institutes of Health to continue a groundbreaking study of arterial plaque. This research could lead to tools that will enable physicians to predict the likelihood of plaque rupture, which is responsible for most heart attacks and strokes.

25 Mar 2010

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

Individuals between 30 and 80 years of age, who have had a transient ischemic attack (TIA) or non-severe stroke within the past 30 days, and who cannot be treated surgically, may be eligible to participate in a Phase III clinical trial of a minimally invasive stenting procedure at the Cedars-Sinai Neurovascular Center. The study will focus specifically on patients who have had an intracranial artery narrowed by at least 70 percent and who are experiencing recurrent strokes or TIAs despite being on anti-clotting medication.

19 Mar 2010

Hybrid revascularization procedure is safe and feasible for left main coronary artery stenosis

The left main coronary artery provides most of the blood to the heart, and current guidelines call for patients with blockages in this artery to undergo bypass surgery.

16 Mar 2010

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

Boston Scientific Corporation today announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS® Element™ Paclitaxel-Eluting Stent System compared to the TAXUS® Express2™ Paclitaxel-Eluting Stent System.

16 Mar 2010

PERSEUS clinical program comparing TAXUS Element Stent to prior-generation stents: 12-month results

Angiotech Pharmaceuticals, Inc. today announced that its corporate partner, Boston Scientific Corporation, announced 12-month results from its PERSEUS clinical program that demonstrated positive safety and efficacy outcomes in workhorse lesions for the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Stent System compared to the TAXUS(R) Express(TM) Paclitaxel-Eluting Stent System.

16 Mar 2010

Drug-eluting stents offer new hope to patients with critical limb ischemia

In the United States, more than 100,000 amputations are performed each year on individuals with critical limb ischemia, the most severe form of peripheral arterial disease (PAD). The number one priority in treating these patients is to re-establish blood flow to avoid limb amputation.

16 Mar 2010

Medtronic announces positive STOP AF clinical trial data at 59th American College of Cardiology session

Medtronic, Inc. today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial during late-breaking sessions at the 59th Annual Scientific Session of the American College of Cardiology in Atlanta. The data showed superiority over anti-arrhythmic drugs, with 69.9 percent of patients with paroxysmal atrial fibrillation (PAF) treated with the Arctic Front® Cardiac CryoAblation Catheter System remaining free of atrial fibrillation (AF) one year after cryoablation, compared to 7.3 percent on drug therapy.

15 Mar 2010

Stenosis News and Research

Interventional Spine to present at and participate as sponsor of Spine Technology Summit

Surgical treatment for certain injuries helps NFL athletes return to the game faster

Magnetically guided nanoparticles for delivering DNA, cells and drugs

First US implant of Interventional Spine's RENEW Interspinous Allograft Technology for LSS

Alphatec Holdings prices underwritten public offering of common stock

Alphatec Holdings proposes 8 million common stock public offering

Alphatec Spine's first-quarter preliminary consolidated revenues up 25.6%

Complex back surgeries skyrocket, raising concerns about cost, complications

Frequency of complex fusion procedures for lower back increased among Medicare recipients

Medtronic to appeal U.S. jury verdict in CoreValve system patent infringement case

Enrollment complete in Paradigm Spine's comparative study of coflex interlaminar technology

Alphatec Holdings closes acquisition of Scient'x Groupe

AngioScore receives FDA marketing clearance for PTA Scoring Balloon Catheter

NIH grants $1.4 Million to WPI to continue study of arterial plaque

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

Hybrid revascularization procedure is safe and feasible for left main coronary artery stenosis

PERSEUS clinical program demonstrates positive results of TAXUS Element Paclitaxel-Eluting Stent System

PERSEUS clinical program comparing TAXUS Element Stent to prior-generation stents: 12-month results

Drug-eluting stents offer new hope to patients with critical limb ischemia

Medtronic announces positive STOP AF clinical trial data at 59th American College of Cardiology session

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News